Anzeige
Mehr »
Samstag, 16.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JPMY | ISIN: US64131A1051 | Ticker-Symbol: NRC
Tradegate
15.08.25 | 18:08
2,935 Euro
+2,62 % +0,075
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURONETICS INC Chart 1 Jahr
5-Tage-Chart
NEURONETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,8202,90015.08.
2,8452,87015.08.

Aktuelle News zur NEURONETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.08.Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)72MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
06.08.Canaccord Genuity lowers Neuronetics stock price target on margin concerns4
05.08.Neuronetics adjusts 2025 gross margin guidance to 48%-50% as Greenbrook revenue mix rises2
05.08.Neuronetics, Inc. Q2 Sales Increase1
05.08.Neuronetics Q2 2025 slides reveal strong revenue growth, path to profitability1
NEURONETICS Aktie jetzt für 0€ handeln
05.08.Neuronetics: EPS verfehlt Schätzungen um 0,07 $ - Umsatz besser als erwartet1
05.08.Neuronetics, Inc. - 10-Q, Quarterly Report1
05.08.Neuronetics Reports Second Quarter 2025 Financial and Operating Results240Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used...
► Artikel lesen
05.08.Neuronetics, Inc. - 8-K, Current Report-
30.07.Neuronetics: NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents1
28.07.JMP bestätigt für Neuronetics-Aktie "Market Outperform"-Rating vor Q2-Zahlen2
28.07.JMP reiterates Market Outperform rating on Neuronetics stock ahead of Q2 earnings2
15.07.Neuronetics names Steven Pfanstiel chief financial officer2
15.07.Neuronetics Appoints Steven Pfanstiel As CFO; Reaffirms Q2, FY25 Guidance1
15.07.Neuronetics appoints Steven Pfanstiel as chief financial officer1
15.07.Neuronetics Appoints New Chief Financial Officer104Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession...
► Artikel lesen
15.07.Neuronetics, Inc. - 8-K, Current Report1
09.07.Neuronetics Showcases NeuroStar TMS Data at Clinical TMS Meeting2
20.06.Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)121MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
10.06.Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program2
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1